Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 9, pp. 841-851
Open Access | Times Cited: 1441

Showing 1-25 of 1441 citing articles:

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino, Peter J Grant, Victor Aboyans, et al.
European Heart Journal (2019) Vol. 41, Iss. 2, pp. 255-323
Open Access | Times Cited: 4130
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Søren Lund Kristensen, Rasmus Rørth, Pardeep S. Jhund, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 10, pp. 776-785
Open Access | Times Cited: 1291
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 24, pp. 2221-2232
Open Access | Times Cited: 1093
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1051
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 992
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 962
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 10, pp. 653-662
Open Access | Times Cited: 947
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 714
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 698
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 587
Advances in oral peptide therapeutics
Daniel J. Drucker
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 4, pp. 277-289
Closed Access | Times Cited: 503
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetologia (2019) Vol. 63, Iss. 2, pp. 221-228
Open Access | Times Cited: 464
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

Diabetes Care (2019) Vol. 43, Iss. Supplement_1, pp. S111-S134
Open Access | Times Cited: 448
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021

Diabetes Care (2020) Vol. 44, Iss. Supplement_1, pp. S125-S150
Closed Access | Times Cited: 399
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 391
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 387
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 352
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S158-S190
Open Access | Times Cited: 346
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology
Russian Journal of Cardiology (2020) Vol. 25, Iss. 11, pp. 4083-4083
Open Access | Times Cited: 336
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani, et al.
Diabetes Care (2019) Vol. 42, Iss. 12, pp. 2272-2281
Open Access | Times Cited: 329
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 321
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 281
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Matthew P. Gilbert, Richard E. Pratley
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 273
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
Απόστολος Τσάπας, Ioannis Avgerinos, Thomas Karagiannis, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 278-286
Closed Access | Times Cited: 262
Page 1 - Next Page

Scroll to top